Bapineuzumab misses in first AD trial

Pfizer Inc. (NYSE:PFE) and partner Johnson & Johnson (NYSE:JNJ) said IV bapineuzumab missed the co-primary endpoints in the Phase III Study 302 trial to treat mild to moderate Alzheimer's disease. Bapineuzumab did not significantly improve cognition as measured by Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) scores and function as measured by Disability Assessment for Dementia (DAD) scores from baseline to 18 months vs. placebo. The double-blind, North American trial enrolled about 1,100 patients with mild to moderate AD who are carriers of the apolipoprotein E epsilon 4 (APOE4) genotype. Bapineuzumab is a humanized mAb against beta amyloid. ...